{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir+long-acting",
    "query": {
      "intervention": "Cabotegravir long-acting"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 55,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cabotegravir+long-acting&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T03:46:55.090Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02076178",
      "title": "Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "744 Tablet",
          "type": "DRUG"
        },
        {
          "name": "744 LA Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2014-03-27",
      "completion_date": "2016-02-23",
      "has_results": true,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076178"
    },
    {
      "nct_id": "NCT05152953",
      "title": "Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hiv"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2022-06-08",
      "completion_date": "2023-11-15",
      "has_results": false,
      "last_update_posted_date": "2023-11-29",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 4,
      "location_summary": "Auburn, Alabama • San Francisco, California • Fort Lauderdale, Florida + 1 more",
      "locations": [
        {
          "city": "Auburn",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Kingsville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05152953"
    },
    {
      "nct_id": "NCT03497676",
      "title": "More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Oral Cabotegravir (CAB)",
          "type": "DRUG"
        },
        {
          "name": "Oral Rilpivirine (RPV)",
          "type": "DRUG"
        },
        {
          "name": "Long-Acting Injectable Cabotegravir (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "Long-Acting Injectable Rilpivirine (RPV LA)",
          "type": "DRUG"
        },
        {
          "name": "Combination Antiretroviral Therapy (cART)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 168,
      "start_date": "2019-04-03",
      "completion_date": "2025-04-22",
      "has_results": true,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03497676"
    },
    {
      "nct_id": "NCT02478463",
      "title": "Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir tablet 30 mg once daily for 28 days.",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2017-02-27",
      "completion_date": "2019-07-25",
      "has_results": true,
      "last_update_posted_date": "2020-06-22",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02478463"
    },
    {
      "nct_id": "NCT01754116",
      "title": "A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744 30 mg oral",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 3 mg oral + GSK1265744 30mg oral",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 400 mg (200 nm)",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 400 mg (1 micro m)",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 400 mg (5 micro m)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2013-01",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01754116"
    },
    {
      "nct_id": "NCT06694805",
      "title": "A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CAB LA + RPV LA",
          "type": "DRUG"
        },
        {
          "name": "Oral ART",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2024-12-02",
      "completion_date": "2028-06-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06694805"
    },
    {
      "nct_id": "NCT06411223",
      "title": "Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hiv"
      ],
      "interventions": [
        {
          "name": "Collaborative drug therapy management model",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cabotegravir/Rilpivirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-08-01",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411223"
    },
    {
      "nct_id": "NCT03635788",
      "title": "The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Standard of Care (SOC) Oral ART",
          "type": "DRUG"
        },
        {
          "name": "Oral RPV",
          "type": "DRUG"
        },
        {
          "name": "Oral CAB",
          "type": "DRUG"
        },
        {
          "name": "RPV-LA Loading Dose",
          "type": "DRUG"
        },
        {
          "name": "CAB-LA Loading Dose",
          "type": "DRUG"
        },
        {
          "name": "RPV-LA Maintenance Dose",
          "type": "DRUG"
        },
        {
          "name": "CAB-LA Maintenance Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 456,
      "start_date": "2019-03-28",
      "completion_date": "2026-08-17",
      "has_results": true,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635788"
    },
    {
      "nct_id": "NCT03856580",
      "title": "Long-acting Biomedical HIV Prevention in Transgender Women",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Prevention",
        "Transgender Women"
      ],
      "interventions": [
        {
          "name": "Alternative long-acting PrEP injection strategies",
          "type": "BEHAVIORAL"
        },
        {
          "name": "mHealth adherence app",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2020-10-23",
      "completion_date": "2023-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-10-04",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03856580"
    },
    {
      "nct_id": "NCT04484337",
      "title": "Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir sodium (Oral Lead In)",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 400 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir 200 mg/mL",
          "type": "DRUG"
        },
        {
          "name": "Topical Non-steroidal anti-inflammatory drug (NSAID)",
          "type": "DRUG"
        },
        {
          "name": "Topical steroid",
          "type": "DRUG"
        },
        {
          "name": "Topical NSAID placebo",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        },
        {
          "name": "Topical steroid placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 138,
      "start_date": "2020-07-31",
      "completion_date": "2023-05-05",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-09-25T03:46:55.090Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04484337"
    }
  ]
}